Brain Tumors Research
Brain Tumor Clinical Trials
The key to finding better treatments for aggressive diseases is the constant collaboration between researchers, clinicians and oncologists — who move therapies swiftly from our on-campus research labs to patients. The quality and frequency of this interaction allows us to get potentially life-extending therapies to our patients quickly.
Recurrent High-Grade Gliomas
NCT05139056: Patients with recurrent high-grade gliomas will soon have the opportunity to participate in a study to assess the safety and effectiveness of multiple doses of neural stem cells in combination with an oncolytic virus.
Patient Enrollment Qualifications
- Age 18 years or older
- Diagnosed with recurrent high-grade glioma
_______________________
NCT04214392: We're recruiting for a study on the possible benefits and optimal doses of CAR T cells with a chlorotoxin tumor-targeting domain to treat MMP2+ recurrent high-grade gliomas.
Patient Enrollment Qualifications
- Age 18 years or older
- Diagnosed with recurrent high-grade glioma
_______________________
NCT04003649: We're recruiting patients for a study that combines two types of immunotherapy using CAR T cells together with nivolumab and/or ipilimumab.
Patient Enrollment Qualifications
- Age 18 years or older
- Diagnosed with recurrent high-grade glioma
_______________________
NCT04661384: Patients with leptomeningeal disease may be eligible to participate in a study of CAR T cell therapy to assess the benefits of treatment using brain tumor-specific immune cells.
Patient Enrollment Qualifications
- Age 18 years or older
- Diagnosed with leptomeningeal metastases from glioblastoma, ependymoma or medulloblastoma
Learn more about this promising study
_______________________
NCT04510051: Children or young adults with recurrent malignant primary brain tumors can participate in a study to assess the safety and best dose of CAR T cell therapy.
Patient Enrollment Qualifications
- Age 4 to 25 years old
- Recurrent malignant primary brain tumors
Brain Metastases
NCT03696030: We're recruiting for a study to evaluate the possible benefits of CAR T cells in patients with recurrent HER2+ brain and/or leptomeningeal metastases.
Patient Enrollment Qualifications
- Age 18 years or older
- Diagnosed with HER2+ brain and/or leptomeningeal metastases